ORTEC
16.1.2024 15:31:30 CET | Business Wire | Press release
ORTEC, a global provider of decision support software and data science capabilities, is pleased to announce a partnership with investment firm Battery Ventures to accelerate its growth ambitions. This strategic partnership, including a significant investment by Battery, marks a key moment in ORTEC’s existence and positions the company to increase its impact on customers and in core markets globally. With this partnership, ORTEC will be able to further strengthen its leadership position in the US and Europe in the field of supply chain, workforce-management and data science & consulting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116805637/en/
Michael van Duijn (ORTEC CEO) and Zak Ewen (Partner Battery Ventures) (Photo: Business Wire)
Improving the world through data and mathematics
The ORTEC journey started in the early 1980s, when a few passionate Dutch students wanted to show the world the value of mathematics by creating long-term sustainable growth for organizations and society. Specifically, the company’s initial consulting business helped customers leverage data and mathematical models to solve operational problems. Over time, the company developed commercial products that help large enterprises address complex logistical challenges such as last-mile fleet dispatch and route planning; pallet-load planning and optimization; and advanced workforce scheduling and resource planning.
Now, more than 40 years later, ORTEC delivers solutions to over 1,200 customers worldwide to improve business results and make a positive impact on the world. Customers include ASML, Heineken, Coca-Cola Enterprises, Procter & Gamble, Shell, Waitrose, Albert Heijn, G4S, Sodexo and Tesco.
In partnership with Battery, going forward, ORTEC will offer products and services through three new divisions that focus on logistics and routing solutions, workforce-management solutions, and data science and consulting. Battery, which was founded in 1983, is a longtime, global software investor that has made more than 500 investments over the last four decades.
“We are very pleased that Battery Ventures joins ORTEC as a strategic partner. With their knowledge, experience, and network, we can further drive innovation, expand our market reach and create additional impact for our customers,” said Michael van Duijn, ORTEC’s chief executive. “I am proud of the great company we are today and the amazing group of talented employees that create impact for our customers day in and day out. It makes me excited that with this partnership, we have the ingredients to make a more positive impact on the world.”
Shared commitment to long-term growth
The agreement between ORTEC and Battery Ventures highlights a shared commitment to drive innovation, deliver exceptional value to customers, and achieve long-term impact growth. Both parties are confident that the partnership will pave the way for ORTEC to expand its strong position as a leading provider of optimization technology built to solve complex operational challenges in an increasingly data-driven world.
“We’ve gotten to know ORTEC and its founding team over a period of more than 10 years, and during that time we’ve watched the business transform from a consulting-led business into a commercial software company serving the world’s most sophisticated and complex enterprises,” said Zak Ewen, a Battery partner based in London, who joins ORTEC’s board. “Now we’re excited to formally partner with Michael, Aart, Gerrit and the rest of the team to further accelerate the company’s mission.”
Moving forward, ORTEC founders Aart van Beuzekom and Gerrit Timmer remain part of the board and will continue to take care of ORTEC and its future.
About ORTEC
For more than 40 years ORTEC has been supporting many of the world’s best-run organizations to make better data-driven decisions. Our decision support software and data science capabilities enable our customers to improve their business results and make a positive impact on the world. With our 1,000 employees across 13 countries, we help over 1,200 leading customers worldwide to make better choices in an ever-changing environment. Discover more at www.ortec.com.
About Battery Ventures
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on X @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116805637/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom